For patients who stall on standard doses, Novo Nordisk wants to go higher. A 7.2 mg dose of injectable semaglutide is under FDA review, aiming to extend results when weight loss plateaus.
A higher 7.2 mg dose of injectable semaglutide (Wegovy) is under FDA review, above the current 2.4 mg maximum, intended to maximize results for patients who plateau. In the STEP UP Phase 3b trial, the higher dose produced about 18.7 percent average weight loss. It is a dose expansion under review, not yet approved.
Many patients lose meaningfully on GLP-1 medications, then hit a plateau short of their goal.
A higher-dose option under FDA review aims to address exactly that.
Novo Nordisk has filed, and the FDA is reviewing, a higher 7.2 mg dose of injectable semaglutide (Wegovy), above the current maximum of 2.4 mg. The rationale is to maximize efficacy for patients who reach a plateau on standard dosing. In the STEP UP Phase 3b trial, the 7.2 mg dose was associated with about 18.7 percent average weight loss, higher than typically seen with the 2.4 mg dose, positioning it as an option for patients seeking additional results.
This is a dose expansion of an already-approved medicine, semaglutide, rather than a new drug, and as of May 2026 it remained under FDA review. Higher doses can mean greater effect but also warrant attention to tolerability and side effects, which the review process and prescribers weigh.
For consumers, a higher-dose option could help those who stall on current dosing, but more is not automatically better for every individual. Higher doses can increase both benefits and side effects, and suitability depends on the person. The figures describe trial averages, not guarantees. Any move to a higher dose is a clinical decision made with a prescriber, based on response, tolerability, and goals.
Watch the FDA decision on the 7.2 mg dose and how it is positioned, likely for patients who plateau, alongside guidance on tolerability. The broader theme is dose and formulation expansion across the GLP-1 class. For individuals, the practical approach is to discuss plateaus and options with a prescriber rather than self-escalating, and to obtain any semaglutide as the FDA-approved product from a legitimate pharmacy.